Today on Drug Discovery & Development
How the FDA approval of J&J’s Opsynvi could simplify treatment and improve outcomes for PAH patients
Pulmonary arterial hypertension (PAH), a rare, progressive and life-threatening blood vessel disorder, affects some 500 to 1,000 new patients each year in the U.S. FDA recently approved Opsynvi, a first-of-its-kind once-daily single-tablet combination therapy from Johnson & Johnson. “With this approval, our portfolio now includes treatments that address all three guideline-recommended pathways,” said a J&J…Layoff tracker: Mapping the 8,600-plus biotech and pharma layoffs in early 2024
[Updated on April 22, 2024] While a number of biotech startups continue to attract healthy funding amounts, the biotech sector continues to see a significant number of layoffs in 2024 with major cuts hitting firms like Amylyx Pharmaceuticals, Novartis, Genentech and Sanofi. Amylyx Pharmaceuticals is downsizing its workforce by about 70% following the decision to…Drug Discovery and Development See More >
Medincell, AbbVie partner on long-term injectable therapies
Medincell and AbbVie today announced a collaboration to co-develop and commercialize up to six therapeutic products across several areas. The partnership spans multiple therapeutic spaces and indications. Under the agreement, Medincell will use its commercial-stage, long-acting injectable technology platform to formulate innovative therapies. It plans to conduct formulation activities and preclinical studies, including supportive CMC…
Sponsored Content See More >
Genomics/Proteomics See More >
Study combines biomimetic AI, digital twins and multiomics to unveil potential genetic drivers of endometriosis
Endometriosis, a condition where endometrial tissue grows outside the uterus, has a strong genetic underpinning. A new study published in the Journal of Molecular Diagnostics sheds light on this connection. Researchers from a team including Genzeva, LumaGene, RYLTI Biopharma, Brigham & Women’s Hospital of Harvard University and QIAGEN Digital Insights used a unique approach in…
Unleashing a new frontier: The power of germline clinico-genomic data to drive therapeutic development
NVIDIA expands BioNeMo platform with new foundation models and microservices for AI-powered Drug Discovery
Navigating the cancer progression pathway with liquid biopsy
Microsoft and 1910 Genetics: AI-powered partnership targets billion-dollar savings and growth in drug discovery
Infectious Disease See More >
Best-selling pharmaceuticals of 2023 reveal a shift in pharma landscape
Note: This feature on the best-selling pharmaceuticals of 2023 was updated on March 27. Changes are possible as more data become available. Sales of drugs with more than one developer are added together (as in the case of the COVID-19 vaccine Comirnaty) unless one of those companies records the net sales for it, i.e., Dupixent.…
Lumen Bioscience cracks the code on spirulina as a biologics factory for c. diff, metabolic disease and more
Vaccine mega-trials: Rare behemoths in the vaccine trial landscape
Biden names 31 tech hubs: Here are 10 relevant to pharma and biotech
An overview of the RSV vaccine landscape: GSK aims to extend its approval of Arexvy?
Oncology See More >
20 biotech startups attracted almost $3B in Q1 2024 funding
The top 20 healthcare-focused biotech companies collectively raised $2.9 billion in the first quarter of 2024, according to data sourced from Crunchbase. That represents a 161% increase compared to the $1.1 billion raised by the 20 largest funding rounds involving healthcare-focused biotech companies in Q1 2023, indicating more confident bets on the market viability of…